Last reviewed · How we verify
andrographolide sulfonate
At a glance
| Generic name | andrographolide sulfonate |
|---|---|
| Also known as | Xiyanping injection |
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Tonsillitis (PHASE4)
- Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis (PHASE4)
- A Study of Andrographolide Sulfonate in Patients With Acute Exacerbation of Chronic Bronchitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- andrographolide sulfonate CI brief — competitive landscape report
- andrographolide sulfonate updates RSS · CI watch RSS
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. portfolio CI